15 terminated. 15 Phase 2, 5 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Terminated 15 |
| Phase 3 | 5 | Terminated 5 |
| Phase 1 | 1 | Terminated 1 |
Follow Heart Valve Diseases: new trials by email Literature Review of Heart Valve Diseases trials Research Report on Heart Valve Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy MYK-224 - Cardiomyopathy, Hypertrophic | Phase 2 | Terminated | Bristol-Myers Squibb | 18 | 2023-01-18 | 2026-06-02 |
| The Val-CARD Trial Sodium Valproate - Cardiac Valve Disease, Coronary Artery Disease | Phase 1 / Phase 2 | Terminated | University of Leicester | 45 | 2018-11-06 | 2026-08-17 |
| Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis Rivaroxaban 15 mg, Warfarin - Prostheses and Implants, Stroke | Phase 2 / Phase 3 | Terminated | Hospital Geral Roberto Santos | 50 | 2018-07-10 | 2020-05-15 |
| Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline - Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial | Phase 2 | Terminated | Heart Metabolics Limited | 35 | 2016-08-01 | 2017-08-31 |
| Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy Eleclazine, Placebo - Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Terminated | Gilead Sciences | 172 | 2015-02-05 | 2018-09-24 |
| Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL) Edwards Sapien XT Valve - Severe Tricuspid Regurgitation | Phase 2 / Phase 3 | Terminated | Charite University, Berlin, Germany | 28 | 2015-01-01 | 2018-09-18 |
| Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve. Rivaroxaban - Aortic Valve Disease, Heart Valve Prosthesis Implantation | Phase 2 | Terminated | Insel Gruppe AG, University Hospital Bern | 12 | 2012-09-01 | 2017-11-17 |
| Dabigatran Etexilate in Patients With Mechanical Heart Valves warfarin 1mg, dabigatran etexilate intermediate dose, dabigatran etexilate low dose - Heart Valve Diseases | Phase 2 | Terminated | Boehringer Ingelheim | 328 | 2011-10-01 | 2014-08-06 |
| Study to Develop a Non-invasive Marker for Monitoring Myocardial Fibrosis 99mTc-NC100692 - Hypertrophic Cardiomyopathy, Acute Coronary Syndrome | Phase 2 | Terminated | Ottawa Heart Institute Research Corporation | 120 | 2011-05-01 | 2017-04-24 |
| RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery Human fibrinogen concentrate, apheresis platelets - Heart Valve Disease, Coronary Artery Disease | Phase 2 | Terminated | Emory University | 26 | 2011-01-01 | 2018-06-21 |
| V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse V Chordal - Mitral Leaflet Prolapse | Phase 2 | Terminated | Edwards Lifesciences | 5 | 2010-11-01 | 2014-12-23 |
| Radiation Following Percutaneous Balloon Aortic Valvuloplasty to Prevent Restenosis External beam radiation therapy, Sham Control - Aortic Valve Stenosis | Phase 2 / Phase 3 | Terminated | Minneapolis Heart Institute Foundation | 21 | 2007-09-01 | 2019-10-01 |
| Mitral Valve Reconstruction in Chronic Heart Failure (CHF): Identification of Predictors for a Successful Therapy mitral valve repair - Chronic Heart Failure, Mitral Insufficiency | Phase 2 | Terminated | University of Leipzig | 5 | 2006-06-01 | 2016-10-27 |
| CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB) CTI-01 (ethyl pyruvate) - Coronary Disease, Heart Valve Diseases | Phase 2 | Terminated | Critical Therapeutics | 150 | 2005-04-01 | 2006-03-17 |
| Conventional Versus Mini-Sternotomy for Aortic Valve Surgery surgery techniques (sternotomy for aortic valve replacement) - Heart Valve Diseases | Phase 2 / Phase 3 | Terminated | University Hospital, Bordeaux | 78 | 2002-01-01 | 2008-08-15 |
Cardiomyopathy, Hypertrophic (4) · Cardiomyopathy, Hypertrophic, Familial (2) · Coronary Artery Disease (2) · Heart Failure (2) · Acute Coronary Syndrome (1) · Angina Pectoris (1) · Aortic Valve Disease (1) · Aortic Valve Stenosis (1) · Cardiomyopathies (1) · Cardiovascular Diseases (1) · Coronary Disease (1) · Death, Sudden (1) · Dyspnea (1) · Endotoxemia (1)
Cardiovascular Diseases (14) · Heart Diseases (14) · Vascular Diseases (6) · Aortic Valve Disease (5) · Myocardial Ischemia (5) · Aortic Stenosis, Subvalvular (4) · Aortic Valve Stenosis (4) · Pathological Conditions, Signs and Symptoms (4) · Cardiomyopathies (3) · Pathologic Processes (3) · Arterial Occlusive Diseases (2) · Arteriosclerosis (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Coronary Disease (2)
Rivaroxaban (2) · Warfarin (2) · Dabigatran (1) · Fibrinogen (1) · Mitral Valve Annuloplasty (1) · Perhexiline (1) · Sternotomy (1) · Valproic Acid (1) · acarboxyprothrombin (1) · eleclazine (1) · ethyl pyruvate (1) · technetium 99m NC 100692 (1)
Boehringer Ingelheim (1) · Bristol-Myers Squibb (1) · Charite University, Berlin, Germany (1) · Critical Therapeutics (1) · Edwards Lifesciences (1) · Emory University (1) · Gilead Sciences (1) · Heart Metabolics Limited (1) · Hospital Geral Roberto Santos (1) · Insel Gruppe AG, University Hospital Bern (1) · Minneapolis Heart Institute Foundation (1) · Ottawa Heart Institute Research Corporation (1) · University Hospital, Bordeaux (1) · University of Leicester (1) · University of Leipzig (1)
United States (6) · Germany (4) · France (3) · Italy (3) · Canada (2) · Netherlands (2) · Poland (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Brazil (1) · Czechia (1) · Denmark (1) · Israel (1) · Norway (1)
Andre Duraes, PhD (1) · Eva Roost, MD (1) · Gautam Sreeram, MD (1) · Gavin Murphy, MD (1) · Gerard Janvier, Pr (1) · Gerhard Schuler, Prof. (1) · Joachim Calderon, Dr (1) · Kenichi Tanaka, MD, MSc (1) · Marius Roman, MD (1) · Mark Midei, MD (1) · Ottavio Alfiieri, MD (1)
PMID 23718572, PMID 23991661, PMID 30293126, PMID 31837559, PMID 33150497, PMID 39026154
2018 (1)